Oral L-dopa treatment of parkinsonism.
D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use* / Q000652:urine; D004298:Dopamine / Q000096:biosynthesis; D006801:Humans; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy*; D010648:Phenylacetates / Q000097:blood / Q000134:cerebrospinal fluid / Q000652:urine; D026741:Physical Therapy Modalities; D010919:Placebos; D014443:Tyrosine / Q000097:blood
D010648:Phenylacetates; D010919:Placebos; D014443:Tyrosine; D004295:Dihydroxyphenylalanine; D004298:Dopamine